EP1989307B1 — NOVEL TANDEM siRNAS
Assigned to Quark Pharmaceuticals Inc · Expires 2012-08-08 · 14y expired
What this patent protects
The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of two or more target genes. In particular, the present invention discloses tandem oligoribonucleotid…
USPTO Abstract
The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of two or more target genes. In particular, the present invention discloses tandem oligoribonucleotides which encode two or more inhibitory RNA molecules such as siRNAs, wherein each siRNA may be specific for a different gene. The sense and antisense segments in the siRNAs are connected via either a nucleotide or non-nucleotide linker.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.